AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26880570 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation DES
Number of subjects: 1259
Study 26880570 — intervention group
Group type: COMPARATOR
Intervention: DAPT continuation (6 to 18 additional months)
Number of subjects: 1259
Study 26880570 — intervention group
Group type: COMPARATOR
Intervention: DAPT interruption (aspirin only)
Number of subjects: 1259
Study 24582053 — intervention group
Group type: EXPERIMENTAL
Intervention: DB ACLR with suturing of the ruptured tissue to hamstring graft (n = 5)
Number of subjects: 10
Study 24582053 — intervention group
Group type: COMPARATOR
Intervention: Conventional DB ACLR (n = 5)
Number of subjects: 10
Study 23034698 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 157
Study 23034698 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 157
Study 21223673 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture therapy (AAT) on active points
Number of subjects: 125
Study 21223673 — intervention group
Group type: COMPARATOR
Intervention: AAT on sham points (control group)
Number of subjects: 125
Study 21223673 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AAT on active points and AAT on sham points
Number of subjects: 125
Study 18520389 — intervention group
Group type: EXPERIMENTAL
Intervention: Haas expander
Number of subjects: 38
Study 18520389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax expander
Number of subjects: 38
Study 18520389 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Haas and Hyrax)
Number of subjects: 38
Study 16415999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 5 mg
Number of subjects: 42
Study 16415999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 10 mg
Number of subjects: 42
Study 16415999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 20 mg
Number of subjects: 42
Study 16415999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 40 mg
Number of subjects: 42
Study 16415999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 60 mg
Number of subjects: 42
Study 11839712 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.3 pmol/kg/min
Number of subjects: 11
Study 11839712 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.9 pmol/kg/min
Number of subjects: 11
Study 11839712 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study 11839712 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 11
Study 10585387 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Walkers (LW; 20-40 min/bout)
Number of subjects: 56
Study 10585387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Walkers (IW; 10-15 min/bout)
Number of subjects: 56
Study 10585387 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Walkers (SW; 5-10 min/bout)
Number of subjects: 56
Study 10585387 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 56
Study 7538555 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5 micrograms/kg/d beginning on day + 1 following transplant
Number of subjects: 41
Study 7538555 — intervention group
Group type: COMPARATOR
Intervention: Standard posttransplant supportive care without HGF
Number of subjects: 41
Study 7538555 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF in patients who received PBSC alone
Number of subjects: 41
Study 7538555 — intervention group
Group type: COMPARATOR
Intervention: Control in patients who received PBSC alone
Number of subjects: 41
Study 7538555 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF in patients who received PBSC with bone marrow
Number of subjects: 41
Study 7538555 — intervention group
Group type: COMPARATOR
Intervention: Control in patients who received PBSC with bone marrow
Number of subjects: 41
Study 7538555 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 41
Study 7538555 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study 2157240 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose proton treatment
Number of subjects: 50
Study 7003869 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate node dissection
Number of subjects: 553
Study 7003869 — intervention group
Group type: COMPARATOR
Intervention: Delayed node dissection
Number of subjects: 553
Study 30999679 — intervention group
Group type: EXPERIMENTAL
Intervention: Real neck taping for 30 consecutive days
Number of subjects: 12
Study 30999679 — intervention group
Group type: COMPARATOR
Intervention: Sham neck taping for 30 consecutive days
Number of subjects: 12
Study 27977473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide 1.25 mg
Number of subjects: 397
Study 27977473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide 1.75 mg
Number of subjects: 397
Study 27977473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 25445335 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured brief advice based on the 5 A's model
Number of subjects: 467
Study 25445335 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 467
Study 23415629 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching adherence intervention
Number of subjects: 54
Study 23415629 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 54
Study 20465356 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased perceptual selection demands (ventral regions activity)
Number of subjects: 0
Study 20465356 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased action selection demands (dorsal regions activity)
Number of subjects: 0
Study 20465356 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased action selection demands (lateral pFC activity)
Number of subjects: 0
Study 20465356 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice response times
Number of subjects: 0
Study 19897780 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored programs
Number of subjects: 50
Study 19897780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 19897780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 17222848 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 120
Study 17222848 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes without plaques
Number of subjects: 120
Study 17222848 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes with atherosclerotic plaques
Number of subjects: 120
Study 17222848 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 120
Study 15209651 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis screening program participants
Number of subjects: 9268
Study 15209651 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants of osteoporosis screening program
Number of subjects: 9268
Study 10873400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation
Number of subjects: 0
Study 10873400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation (inpatient setting)
Number of subjects: 0
Study 10873400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation (outpatient setting)
Number of subjects: 0
Study 10873400 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy using radiation alone
Number of subjects: 0
Study 9524790 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% azelastine eye drops
Number of subjects: 278
Study 9524790 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% azelastine eye drops
Number of subjects: 278
Study 9524790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 8249563 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of morphine in saline
Number of subjects: 12
Study 8249563 — intervention group
Group type: COMPARATOR
Intervention: saline only
Number of subjects: 12
Study 2411072 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 10% zinc sulfate in Aquaphor ointment
Number of subjects: 47
Study 2411072 — intervention group
Group type: COMPARATOR
Intervention: Aquaphor alone
Number of subjects: 47
Study 31256912 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolithic lithium disilicate occlusal onlays
Number of subjects: 7
Study 29941520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin activity (PRA) at 28 weeks
Number of subjects: 108
Study 29941520 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin activity (PRA) at 36 weeks
Number of subjects: 108
Study 29941520 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine aldosterone (Ualdo) at 28 weeks
Number of subjects: 108
Study 29941520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure
Number of subjects: 108
Study 29941520 — intervention group
Group type: EXPERIMENTAL
Intervention: PRA and Ualdo correlation
Number of subjects: 108
Study 29941520 — intervention group
Group type: EXPERIMENTAL
Intervention: PRA and Ualdo in women of black race
Number of subjects: 108
Study 25988938 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free powder lidocaine delivery system
Number of subjects: 693
Study 25988938 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 693
Study 25033919 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day
Number of subjects: 90
Study 25033919 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (twice a week for 4 weeks)
Number of subjects: 90
Study 25033919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25033919 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin, Acupuncture, Placebo
Number of subjects: 90
Study 23043381 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise group (150 minutes of moderate to vigorous physical activity per week for six weeks)
Number of subjects: 146
Study 23043381 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive exercise group (300 minutes of moderate to vigorous physical activity per week for six weeks)
Number of subjects: 146
Study 23043381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructions regarding lifestyle)
Number of subjects: 146
Study 20728565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/high red meat (HP) diet
Number of subjects: 33
Study 20728565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 33
Study 20728565 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-weight-loss)
Number of subjects: 33
Study 18612188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin, 80 mg/day, orally for 6 weeks
Number of subjects: 85
Study 18612188 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle modification only)
Number of subjects: 85
Study 16037178 — intervention group
Group type: EXPERIMENTAL
Intervention: RM group (0.25% ropivacaine and morphine 0.2 mg/mL)
Number of subjects: 39
Study 16037178 — intervention group
Group type: EXPERIMENTAL
Intervention: RMK group (0.25% ropivacaine, morphine 0.2 mg/mL and ketorolac 1 mg/mL)
Number of subjects: 39
Study 16037178 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 39
Study 11922560 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily (n = 93)
Number of subjects: 182
Study 11922560 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine 2 g b.i.d. (n = 89)
Number of subjects: 182
Study 11922560 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily
Number of subjects: 182
Study 11922560 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine 2 g b.i.d.
Number of subjects: 182
Study 10961629 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy nurse specialist
Number of subjects: 90
Study 10961629 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 90
Study 8780276 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine 2 micrograms/kg
Number of subjects: 50
Study 8780276 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine 4 micrograms/kg
Number of subjects: 50
Study 8780276 — intervention group
Group type: COMPARATOR
Intervention: Intravenous buprenorphine 2 micrograms/kg
Number of subjects: 50
Study 8780276 — intervention group
Group type: COMPARATOR
Intervention: Intravenous buprenorphine 4 micrograms/kg
Number of subjects: 50
Study 1632979 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural leukocyte alpha interferon (IFN) administered at 6 MU i.m. daily for 4 weeks and thereafter 3 times per week for 2 months, combined with radiotherapy (2 Gy daily, 5 fractions per week)
Number of subjects: 22
Study 1632979 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (control)
Number of subjects: 22
Study 1632979 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural leukocyte alpha interferon (IFN)
Number of subjects: 22
Study 6708391 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin administration (plasma levels 1.55 +/‐ 0.27 ng/ml) lasting 35 days
Number of subjects: 43
Study 6708391 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin administration with maximal stimulation of adrenal and gonadal glands by ACTH and hCG
Number of subjects: 43
Study 6708391 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin administration over a period of 150‐210 days
Number of subjects: 43
Study 6708391 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐methyldigoxin, beta‐acetyldigoxin, and digitoxin (mean duration: 1.9 years)
Number of subjects: 43
Study 31900148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical laboratory services satisfaction survey
Number of subjects: 2399
Study 31900148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissatisfaction factors
Number of subjects: 2399
Study 31900148 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational status and distance
Number of subjects: 2399
Study 31885908 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 steps
Number of subjects: 92
Study 31885908 — intervention group
Group type: EXPERIMENTAL
Intervention: 12,500 steps
Number of subjects: 92
Study 31885908 — intervention group
Group type: EXPERIMENTAL
Intervention: 15,000 steps
Number of subjects: 92
Study 31885908 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 92
Study 28302130 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction arthroplasty combined with arthroscopic microfracture
Number of subjects: 96
Study 28302130 — intervention group
Group type: COMPARATOR
Intervention: Distraction arthroplasty alone
Number of subjects: 96
Study 26363127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidcombe Program
Number of subjects: 13
Study 26363127 — intervention group
Group type: EXPERIMENTAL
Intervention: Demands and Capacities-based treatment
Number of subjects: 13
Study 26363127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidcombe Program and Demands and Capacities-based treatment
Number of subjects: 13
Study 26363127 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in RESTART-trial
Number of subjects: 13
Study 23517837 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 7021
Study 23517837 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access (low volume centers)
Number of subjects: 7021
Study 23517837 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access (middle volume centers)
Number of subjects: 7021
Study 23517837 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access (high volume centers)
Number of subjects: 7021
Study 23517837 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural volume
Number of subjects: 7021
Study 21474646 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 616
Study 21474646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 17994292 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg/day)
Number of subjects: 27179
Study 17994292 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg/day)
Number of subjects: 27179
Study 17994292 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27179
Study 16426960 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified beverage
Number of subjects: 608
Study 16426960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 12601257 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF) during radiological procedures (RxP)
Number of subjects: 26
Study 12601257 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not receiving CVVHDF)
Number of subjects: 26
Study 11512693 — intervention group
Group type: EXPERIMENTAL
Intervention: JOAS
Number of subjects: 81
Study 11512693 — intervention group
Group type: EXPERIMENTAL
Intervention: AOAS
Number of subjects: 81
Study 11512693 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 81
Study 9640080 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) measurement in patients with iron deficiency
Number of subjects: 96
Study 9640080 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) measurement in patients with ACD
Number of subjects: 96
Study 9640080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ZPP measurement with ferritin and peripheral blood morphology
Number of subjects: 96
Study 9640080 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc protoporphyrin (ZPP) level higher than 4.55 micrograms/gHb
Number of subjects: 96
Study 8102829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium doses ranging from 0.1 to 0.3 mg kg‐1
Number of subjects: 0
Study 3813189 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (0.75 mg/kg)
Number of subjects: 10
Study 3813189 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (0.35 mg/kg)
Number of subjects: 10
Study 2628130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin bound to sulbactam (sultamicillin)
Number of subjects: 16
Study 2628130 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin with clavulanic acid
Number of subjects: 16
Study 31348248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sogyeonghwalhyeol-tang
Number of subjects: 72
Study 31348248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 28750894 — intervention group
Group type: EXPERIMENTAL
Intervention: Torus printlet
Number of subjects: 50
Study 28750894 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule and disc shaped printlets
Number of subjects: 50
Study 28750894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphere printlet
Number of subjects: 50
Study 28750894 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller printlet sizes
Number of subjects: 50
Study 28750894 — intervention group
Group type: EXPERIMENTAL
Intervention: Printlet colour
Number of subjects: 50
Study 28750894 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptability of torus printlets
Number of subjects: 50
Study 25138115 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinomed orthosis
Number of subjects: 0
Study 25138115 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteomed orthosis
Number of subjects: 0
Study 25138115 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinomed active orthosis
Number of subjects: 0
Study 25138115 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine-X orthosis
Number of subjects: 0
Study 23041092 — intervention group
Group type: EXPERIMENTAL
Intervention: High vWF/ADAMTS13-ratio (>27.57)
Number of subjects: 269
Study 23041092 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAMTS13 ≤ 49.77%
Number of subjects: 269
Study 23041092 — intervention group
Group type: EXPERIMENTAL
Intervention: vWF > 1434.92 mU/ml
Number of subjects: 269
Study 23041092 — intervention group
Group type: EXPERIMENTAL
Intervention: High vWF/ADAMTS13-ratio (>27.57) in low and intermediate risk patients (according to CHADS2-score)
Number of subjects: 269
Study 21474219 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-GLA diet
Number of subjects: 160
Study 21474219 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 160
Study 17947225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus cisplatin/vinorelbine
Number of subjects: 86
Study 17947225 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/vinorelbine alone
Number of subjects: 86
Study 16492211 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood ketone monitoring (blood glucose monitor that also measures blood 3-OHB)
Number of subjects: 123
Study 16492211 — intervention group
Group type: COMPARATOR
Intervention: Urine ketone testing (monitor plus urine ketone strips)
Number of subjects: 123
Study 15106359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 90
Study 15106359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 90
Study 15106359 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium 1000 mg/day)
Number of subjects: 90
Study 11334476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combiphasic EE/DSG (25 microg desogestrel and 40 microg ethinylestradiol for 7 days followed by 125 microg desogestrel and 30 microg ethinylestradiol for 15 days)
Number of subjects: 172
Study 11334476 — intervention group
Group type: COMPARATOR
Intervention: EE35/CPA (2.0 mg cyproterone acetate and 35 microg ethinylestradiol for 21 days)
Number of subjects: 172
Study 9127977 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (twice-weekly sessions of low intensity movements for one year)
Number of subjects: 110
Study 9127977 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 110
Study 9127977 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 110
Study 7525246 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct cortical recordings of ERD and MRCPs during self-paced finger movements
Number of subjects: 23
Study 7525246 — intervention group
Group type: COMPARATOR
Intervention: Scalp-recorded EEGs
Number of subjects: 23